Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 USD | +0.75% | -2.86% | -49.63% |
May. 28 | Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall | MT |
Apr. 22 | Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 27.79M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -12M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-2.47
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.23% |
1 day | +0.75% | ||
1 week | -2.86% | ||
1 month | -15.53% | ||
3 months | -57.63% | ||
6 months | -24.44% | ||
Current year | -49.63% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Hershkovitz
CEO | Chief Executive Officer | 47 | 19-11-15 |
Dror Mevorach
FOU | Founder | 68 | 08-12-31 |
Director of Finance/CFO | 47 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shai Novik
CHM | Chairman | 58 | 13-12-31 |
Avri Havron
BRD | Director/Board Member | 76 | 13-12-31 |
Brian Schwartz
BRD | Director/Board Member | 52 | 20-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.36 | +0.75% | 7,239 |
24-05-30 | 1.35 | +3.05% | 20,225 |
24-05-29 | 1.31 | -5.07% | 42,419 |
24-05-28 | 1.38 | -1.43% | 266,281 |
24-05-24 | 1.4 | +2.21% | 25,517 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.63% | 27.79M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ENLV Stock